ELOX - Eloxx Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.2200
+0.1600 (+3.94%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.0600
Open4.1000
Bid4.2100 x 900
Ask4.2200 x 800
Day's Range4.0300 - 4.2900
52 Week Range2.8700 - 17.0500
Volume112,788
Avg. Volume180,932
Market Cap168.811M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.4450
Earnings DateNov 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.83
  • Thomson Reuters StreetEvents

    Edited Transcript of ELOX earnings conference call or presentation 5-Nov-19 9:30pm GMT

    Q3 2019 Eloxx Pharmaceuticals Inc Earnings Call

  • GlobeNewswire

    Eloxx Pharmaceuticals Presents New Positive Data for ELX-02 at the American Society of Nephrology (ASN) Kidney Week 2019

    Eloxx Pharmaceuticals, Inc., (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced new data from two abstracts presented at the American Society of Nephrology (ASN) Kidney Week 2019 in Washington, D.C. November 5 -10, 2019. “We are pleased to have presented the results of our completed renal impairment study at Kidney Week, which have been important in defining the appropriate doses for patients with renal insufficiency.

  • GlobeNewswire

    Eloxx Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results and Provides Business Update

    -Presented Positive Phase 1 Data from SAD and MAD Studies at North American Cystic Fibrosis Conference -On track to report top line Phase 2 data in nephropathic cystinosis this.

  • GlobeNewswire

    Eloxx Pharmaceuticals Presents Positive Data for Lead Investigational Drug, ELX-02, at the North American Cystic Fibrosis Conference (NACFC)

    Eloxx Pharmaceuticals, Inc. (“Eloxx”), (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced positive data demonstrating that ELX-02 results in a pronounced increase in both CFTR protein expression and mRNA stability further supporting its proposed mechanism of action, and that it was well tolerated with no serious adverse events in the Phase 1 program. “We are extremely pleased with the emerging profile of ELX-02 and believe that the consistency of our data with those from previous studies with already approved drugs for cystic fibrosis demonstrating that functional increases in CFTR protein across a growing list of CFTR genotypes were correlated with improvements in FEV1, and lung function derisk our Phase 2 studies,” said Dr. Matthew Goddeeris, Executive Director of Research, Eloxx Pharmaceuticals.

  • PR Newswire

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Eloxx Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , Oct. 23, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • GlobeNewswire

    Eloxx Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on November 5, 2019

    Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal diseases and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that it will release its third quarter 2019 financial and operational results and host a conference call and live webcast on Tuesday, November 5, 2019. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

  • GlobeNewswire

    Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Funding and Support for ELX-02 U.S. Phase 2 Clinical Trial

    WALTHAM, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) --  Eloxx Pharmaceuticals, Inc., (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that the Cystic Fibrosis Therapeutics Development Network has sanctioned its Phase 2 clinical trial protocol in the US for ELX-02 in cystic fibrosis, and the CF Foundation will provide funding and additional resources for the program. “We are very gratified by the CF Foundation’s support as we advance our development program for ELX-02 in cystic fibrosis.

  • GlobeNewswire

    Eloxx Pharmaceuticals to Present at the 2019 Cantor Global Healthcare  Conference on October 3rd, 2019

    Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will make a presentation and host one-on-one meetings with investors at the 2019 Cantor Global Healthcare Conference on October 3rd, 2019 at the InterContinental New York Barclay Hotel. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

  • Thomson Reuters StreetEvents

    Edited Transcript of ELOX earnings conference call or presentation 7-Aug-19 12:30pm GMT

    Q2 2019 Eloxx Pharmaceuticals Inc Earnings Call

  • GlobeNewswire

    Eloxx Pharmaceuticals to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases on September 24, 2019

    Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will host one-on-one meetings with investors at the Oppenheimer Fall Summit focused on Specialty Pharma & Rare Diseases on September 24, 2019 at the Parker New York Hotel. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

  • GlobeNewswire

    Eloxx Pharmaceuticals to Participate in the 14th Annual Citi Biotech Conference on September 5th, 2019

    Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will host one-on-one meetings with investors at the 14th Annual Citi Biotech Conference on September 5th, 2019 at the Four Seasons Boston, Massachusetts. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

  • GlobeNewswire

    Eloxx Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Society of Nephrology (ASN) Kidney Week 2019

    Eloxx Pharmaceuticals, Inc., (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that two abstracts will be presented at the American Society of Nephrology (ASN) Kidney Week 2019 in Washington, D.C. November 5 -10, 2019. “We are pleased to be presenting the results of our completed renal impairment study to the scientific community at the American Society of Nephrology Kidney Week.

  • Eloxx Pharmaceuticals, Inc. (ELOX) Q2 2019 Earnings Call Transcript
    Motley Fool

    Eloxx Pharmaceuticals, Inc. (ELOX) Q2 2019 Earnings Call Transcript

    ELOX earnings call for the period ending June 30, 2019.

  • GlobeNewswire

    Eloxx Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results and Provides Business Update

    Phase 2 cystic fibrosis clinical trial IND is open in the U.S., protocol endorsed by the Cystic Fibrosis Foundation (CFF) Initiated a Phase 2 clinical trial for ELX-02 in.

  • GlobeNewswire

    Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial for ELX-02 in Cystinosis

    Eloxx Pharmaceuticals, Inc., (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that it has initiated a Phase 2 clinical trial (Study 003) for ELX-02 in cystinosis in Canada. Study 003 is a single arm, open label study designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous (SC) ELX-02 in patients with nephropathic cystinosis with at least 1 nonsense mutation in the cystinosin gene. Six patients will be enrolled in the trial, and will be treated with ELX-02 for four weeks with three escalating dose levels.

  • GlobeNewswire

    Eloxx Pharmaceuticals Announces Open Investigational New Drug Application (IND) for a Phase 2 Clinical Trial of ELX-02 in Cystic Fibrosis Patients with the G542X Mutation in the US and Protocol Endorsement from the Cystic Fibrosis Foundation (CFF)

    Eloxx Pharmaceuticals, Inc., (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that an IND for ELX-02 in cystic fibrosis is now open in the U.S. and the Phase 2 clinical trial has been endorsed by the CFF. “We are very pleased that our IND is open in the U.S. and the protocol for our Phase 2 clinical trial in cystic fibrosis has been endorsed by the Cystic Fibrosis Foundation (CFF) in the U.S.  Dr. Ahmet Uluer, Director of the Adult Cystic Fibrosis Program at the Boston Children’s Hospital/Brigham and Women’s Hospital CF Center, has agreed to be the lead study investigator in the U.S., and Professor Kerem Eitan, M.D., Head of the Division of Pediatrics, Children’s Hospital, Hadassah Medical Center, will serve as the Global Lead Investigator.

  • GlobeNewswire

    Eloxx Pharmaceuticals to Present at the 39th Annual Canaccord Genuity Growth Conference on August 8th, 2019

    Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will make a presentation and host one-on-one meetings with investors at the 39th Annual Canaccord Genuity Growth Conference on August 8th, 2019 at the InterContinental Hotel in Boston, Massachusetts. Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases.

  • GlobeNewswire

    Eloxx Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Eloxx Pharmaceuticals, Inc. (“Eloxx”) (ELOX) today announced the closing of its underwritten public offering of 3,833,334 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase an additional 500,000 shares, at a price to the public of $9.00 per share. Eloxx anticipates using the net proceeds from the offering to fund the continued clinical development of ELX-02 in cystic fibrosis and cystinosis, to accelerate development of early-stage programs and for working capital and other general corporate purposes.

  • GlobeNewswire

    Eloxx Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Stock

    Eloxx Pharmaceuticals, Inc. (“Eloxx”) (ELOX) today announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock at a price to the public of $9.00 per share. In addition, Eloxx has granted the underwriters a 30-day option to purchase up to 500,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. Eloxx anticipates using the net proceeds from the offering to fund the continued clinical development of ELX-02 in cystic fibrosis and cystinosis, to accelerate development of early-stage programs and for working capital and other general corporate purposes.

  • Benzinga

    The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 19) Abbott Laboratories (NYSE: ABT ) CareDx Inc (NASDAQ: ...

  • GlobeNewswire

    Eloxx Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Eloxx Pharmaceuticals, Inc. (“Eloxx”) (ELOX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, subject to market and other conditions. Eloxx expects to grant the underwriters an option to purchase up to an additional 15% of the shares of its common stock at the public offering price less the underwriting discount. Eloxx anticipates using the net proceeds from the offering to fund the continued clinical development of ELX-02 in cystic fibrosis and cystinosis, to accelerate development of early-stage programs and for working capital and other general corporate purposes.

  • GlobeNewswire

    Eloxx Pharmaceuticals’ Phase 2 Study of ELX-02 in Cystinosis Receives Authorization of Clinical Trial Application (CTA) by Health Canada and Funding from Genome Quebec and Genome Canada

    Dr. Paul Goodyer, a Professor of Pediatrics at McGill University and recognized leader in hereditary renal disease, will be the principal investigator in the Phase 2 clinical.

  • Why Advanced Micro Devices, Ciena, and Eloxx Pharmaceuticals Jumped Today
    Motley Fool

    Why Advanced Micro Devices, Ciena, and Eloxx Pharmaceuticals Jumped Today

    As the market played a waiting game, good news lifted several companies higher.

  • Benzinga

    Eloxx Pharma Says ELX-02 Data Showed Increases In Key Metric

    Eloxx Pharmaceuticals (NASDAQ: ELOX ) shares spiked higher after the company presented data for its lead investigational drug, ELX-02, at the 42nd European Cystic Fibrosis Society Conference. ELX-02 is ...

  • GlobeNewswire

    Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the 42nd European Cystic Fibrosis Society Conference (ECFS)

    ELX-02 demonstrates dose-responsive pronounced increases in functional CFTR and read-through in organoids, human bronchial epithelial (HBE), and Ussing chamber systems ELX-02.